Myomo

MYO

Market cap $31.9M

Overview Fund Activity

0.8439 USD

-0.0553

6.15%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

0.8508

+0.0069

0.82%

1 day

-6.15%

5 days

-15.19%

1 month

-21.86%

3 months

-69.86%

6 months

-84.46%

Year to date

-86.98%

1 year

-79.42%

5 years

-77.5%

10 years

-99.62%

About: Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).

Employees: 185

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

81% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 16

27% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 22

8% more funds holding

Funds holding: 76 [Q1] → 82 (+6) [Q2]

6.95% more ownership

Funds ownership: 46.39% [Q1] → 53.34% (+6.95%) [Q2]

46% less capital invested

Capital invested by funds: $76.7M [Q1] → $41.5M (-$35.3M) [Q2]

90% less call options, than puts

Call options by funds: $6K | Put options by funds: $60K

100% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 0 (-2) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$5

492% upside

Avg. target

$6.5

670% upside

High target

$8

848% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Sean Lee	$5	Buy Maintained	12 Aug 2025
Craig-Hallum Craig Knickerbocker	$8	Buy Maintained	23 Jun 2025

See Analyst Rankings

Financial journalist opinion

Myomo to Present at the H.C. Wainwright 27th Annual Global Investment Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, president and chief executive officer, and David Henry, chief financial officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 at the Lotte New York Palace.

Myomo to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Zacks Investment Research

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

Myomo, Inc. (MYO) came out with a quarterly loss of $0.11 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.03 per share a year ago.

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

Myomo, Inc. (MYO) Q2 2025 Earnings Conference Call Transcript

Myomo, Inc. (NYSE:MYO ) Q2 2025 Earnings Conference August 11, 2025 4:30 PM ET Company Participants David A. Henry - Chief Financial Officer Paul R.

Myomo, Inc. (MYO) Q2 2025 Earnings Conference Call Transcript

Myomo Reports Second Quarter 2025 Financial and Operating Results

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and six months ended June 30, 2025. Financial and operating highlights for the second quarter of 2025 include the following (all comparisons are with the second quarter of 2024 unless otherwise indicated): Rev.

Myomo Reports Second Quarter 2025 Financial and Operating Results

Myomo to Report Second Quarter 2025 Financial Results on August 11

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the second quarter of 2025 on Monday, August 11, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer question.

Myomo to Report Second Quarter 2025 Financial Results on August 11

Myomo Provides Highlights of Today's Investor & Analyst Day Event

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, will host an Investor & Analyst Day event today from 10 a.m. to 3 p.m. Eastern time during which management will provide an in-depth review of the Company's business model, provide a tour of its new headquarters and manufacturing facility and discuss l.

Myomo Provides Highlights of Today's Investor & Analyst Day Event

Myomo, Inc. (MYO) Q1 2025 Earnings Call Transcript

Myomo, Inc. (NYSE:MYO ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Tirth Patel - Alliance Advisors, Investor Relations Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Scott Henry - Alliance Global Partners Anthony Vendetti - Maxim Group Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon, and welcome to the Myomo's First Quarter 2025 Earnings Conference Call.

Myomo, Inc. (MYO) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates

Myomo, Inc. (MYO) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.10 per share a year ago.

Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates

Myomo Reports First Quarter 2025 Financial and Operating Results

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025. Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated): Revenue was.

Myomo Reports First Quarter 2025 Financial and Operating Results

Myomo to Host Investor & Analyst Day Event on June 18, 2025

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces the Company will be hosting its first-ever Investor & Analyst Day event on Wednesday, June 18, 2025. The event will take place at Myomo's new corporate headquarters and manufacturing facility in Burlington, Mass., and will offer an in-depth l.

Myomo to Host Investor & Analyst Day Event on June 18, 2025

See News Rankings

Charts implemented using Lightweight Charts™